{"id":"hiv-anti-retroviral-background-therapy","safety":{"commonSideEffects":[{"rate":"10%","effect":"Nausea"},{"rate":"8%","effect":"Diarrhea"},{"rate":"6%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL3672477","moleculeType":"Small molecule","molecularWeight":"317.28"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Theratechnologies' drug works by binding to the CCR5 receptor on the surface of host cells, preventing HIV from entering and replicating within those cells.","oneSentence":"Inhibits HIV replication by targeting the CCR5 receptor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:50:11.487Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection"}]},"trialDetails":[{"nctId":"NCT05383456","phase":"","title":"The Visceral Adiposity Measurement and Observation Study","status":"COMPLETED","sponsor":"Theratechnologies","startDate":"2022-04-18","conditions":"HIV, HIV-Infections, HIV-1-infection","enrollment":196},{"nctId":"NCT00031044","phase":"PHASE1, PHASE2","title":"Adding New Drugs for HIV Infected Patients Failing Current Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT00300573","phase":"PHASE2","title":"Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2006-04","conditions":"HIV Infections, Human Immunodeficiency Virus","enrollment":250},{"nctId":"NCT00756730","phase":"PHASE4","title":"Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r","status":"COMPLETED","sponsor":"Community Research Initiative of New England","startDate":"2008-09","conditions":"HIV Infections","enrollment":49},{"nctId":"NCT00022763","phase":"PHASE2","title":"T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and Adolescents","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2001-08","conditions":"HIV Infections","enrollment":52},{"nctId":"NCT00440271","phase":"PHASE3","title":"SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2007-02","conditions":"HIV Infections","enrollment":33},{"nctId":"NCT01189695","phase":"PHASE4","title":"Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure","status":"COMPLETED","sponsor":"Bamrasnaradura Infectious Diseases Institute","startDate":"2010-12","conditions":"HIV, AIDS, Lopinavir","enrollment":63},{"nctId":"NCT01190124","phase":"","title":"Raltegravir With Optimized Background Therapy (OBT) in Multiple Experienced HIV-infected Patients","status":"COMPLETED","sponsor":"Doroana, Maria Manuela, M.D.","startDate":"2010-04","conditions":"HIV Infections","enrollment":151},{"nctId":"NCT00021554","phase":"PHASE3","title":"T-20 in HIV Patients With Prior Drug Treatment and/or Resistance to Each of the Three Classes of Anti-HIV Drugs","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"HIV Infections","enrollment":525},{"nctId":"NCT00008528","phase":"PHASE3","title":"T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"HIV Infections","enrollment":525}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"HIV Anti-retroviral Background Therapy","genericName":"HIV Anti-retroviral Background Therapy","companyName":"Theratechnologies","companyId":"theratechnologies","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhibits HIV replication by targeting the CCR5 receptor Used for HIV-1 infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}